Heterozygous Familial Hypercholesterolemia (HeFH) Overview
Learn About Heterozygous Familial Hypercholesterolemia (HeFH)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Mika Hori practices in Nagoya, Japan. Hori is rated as an Elite expert by MediFind in the treatment of Heterozygous Familial Hypercholesterolemia (HeFH). Their top areas of expertise are Heterozygous Familial Hypercholesterolemia (HeFH), Familial Hypercholesterolemia, High Cholesterol, Defective Apolipoprotein B-100, and Pancreaticoduodenectomy.
Mariko Shiba-Harada practices in Osaka, Japan. Ms. Shiba-Harada is rated as an Elite expert by MediFind in the treatment of Heterozygous Familial Hypercholesterolemia (HeFH). Her top areas of expertise are Heterozygous Familial Hypercholesterolemia (HeFH), Familial Hypercholesterolemia, High Cholesterol, and Homozygous Familial Hypercholesterolemia (HoFH).
Frederick Raal practices in Johannesburg, South Africa. Mr. Raal is rated as an Elite expert by MediFind in the treatment of Heterozygous Familial Hypercholesterolemia (HeFH). His top areas of expertise are Homozygous Familial Hypercholesterolemia (HoFH), Heterozygous Familial Hypercholesterolemia (HeFH), Familial Hypercholesterolemia, and High Cholesterol.
Summary: VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating ...
Summary: This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to \<12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDLC).
